Celldex Therapeutics Stock (NASDAQ: CLDX)

Celldex Therapeutics

CELLDEX THERAPEUTICS INC

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Oil,Production,Rig,In,The,Sea,,Landscape.,Red,Sea,,Egypt,

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AIHS

CHSN

CLDX

SBET

UMAC

Crude Oil Rises 6%; US Consumer Sentiment Surges In June

Display,Of,Stock,Market,Quotes

Movers

ANNA

CCCM

Highest Performances Holdings Inc. - American Depository Shares

MAAS

PHAT

URGN

Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday

Sep,16,,2019,Milpitas, - ,Ca, - ,Usa,-,Kohl's

Initiation

Pre-Market Outlook

Analyst Ratings

CODX

This Kohl&#39;s Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics Inc

Press Releases

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Health Care

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

General

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

AGIO

Akebia Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Beam Therapeutics

Biohaven

CareDx

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Janux Therapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

MannKind

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Arcus Biosciences

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Verve Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

HC Wainwright & Co.

Goldman Sachs

Morgan Stanley

Canaccord Genuity

Comments

Celldex Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell